



Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC

Leuven, BELGIUM, Boston, MA, US – December 1, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation¹ it has received transparency notifications as follows:

Oxurion received a first transparency notification on November 22, 2023, from Atlas Special Opportunities, LLC indicating that as of November 13, 2023, it held 0 shares of the then outstanding 3,112,043,514 shares, and therefore crossed below the threshold (3%) by virtue of the sale of voting securities. See Annex 1.

Oxurion received a second transparency notification on November 29, 2023, from Atlas Special Opportunities, LLC indicating that as of November 17, 2023, it held 241,545,893 shares of the then outstanding 3,489,458,972 shares, and therefore crossed above the threshold (5%) by virtue of the acquisition and sale of voting securities. See Annex 2.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV
Tom Graney
Chief Executive Officer
Tel: +32 16 75 13 10
tom.graney@oxurion.com


Michael Dillen Chief Business Officer Tel: +32 16 75 13 10 michael.dillen@oxurion.com <u>US</u>
<u>Conway Communications</u>

Mary T. Conway

<u>mtconway@conwaycommsir.com</u>

^{1.} Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1



9) Denominator

3,112,043,514

Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voti	ing rights	% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities LLC	232,919,254	0		0.00%	
	TOTAL	0	0	0.00%	0.00%



Start with "groups" of holders. Add subtotals with Σ , and then finish with the persons who are "alone". For groups, start with the ultimate controlling natural person or legal entity.

The totals, subtotals and % will be updated once you have clicked on <CALCULATE>.

Sign Envelope ID: F1BD79BA-C3D9-4995-8CCF-60F38B4394FF

B) Equivalent financial instruments	After the transaction]		
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement	
	TOTAL			0	0.00%		_



The totals will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)		# of voting rights	% of voting rights	
	CALCULATE	0	0.00%	


Additional information On 9 November 2023, Aflas Special Opportunities LLC hald 157,227,832 shares in Oxurion NV (= 5.05%, with denominator = 3,112,043,514). On 13 November 2023, Aflas Special Opportunities LLC sold 91,549,447 shares in Oxurion NV, as a result of which its shareholding decreased to 0 shares (= 0.00%, with denominator = 3,112,043,514). On 13 November 2023, Aflas Special Opportunities LLC sold 91,549,447 shares in Oxurion NV, as a result of which its shareholding decreased to 0 shares (= 0.00%, with denominator = 3,112,043,514). On 13 November 2023, Aflas Special Opportunities LLC sold 91,549,447 shares in Oxurion NV, as a result of which its shareholding decreased to 0 shares (= 0.00%, with denominator = 3,112,043,514). Done at New York On 17/11/2023 (IDDMMYYYY)

Signature Patrick Vance

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Name & capacity Patrick Vance, proxyholder

ANNEX 2



9) Denominator

3,489,458,972

Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities LLC	0	241,545,893		6.92%	
TOTAL		241,545,893	0	6.92%	0.00%

Start with "groups" of holders. Add subtotals with \sum_{i} , and then finish with the persons who are "alone". For groups, start with the ultimate controlling natural person or legal entity.

The totals, subtotals and % will be updated once you have clicked on <CALCULATE>.

gn Envelope ID: 7F03E731-92D9-4BC6-8FCE-52174CF89325

B) Equivalent financial instruments	After the transaction					
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
	TOTAL			0	0.00%	

The totals will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)		# of voting rights	% of voting rights
	CALCULATE	241,545,893	6.92%

+

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable Atlas Special Opportunities LLC is not a controlled entity. 12) In case of proxy voting for only one GM Will cease to hold / will hold again 13) Additional information On 15 November 2023, Atlas Special Opportunities LLC purchased 135,869,565 shares in Oxurion NV, as a result of which its shareholding increased to 377,415,458 shares (= 6,92%, with denominator = 3,489,458,972). On the same day, Atlas Special Opportunities LLC purchased 241,545,893 shares in Oxurion NV, as a result of which its shareholding increased to 377,415,458 shares (= 6,92%, with denominator = 3,489,458,972). On the same day, Atlas Special Opportunities LLC sold 135,869,565 shares in Oxurion NV, as a result of which its shareholding increased to 241,545,893 shares (= 6,92%, with denominator = 3,489,458,972).

Done at New York	<u> </u>		
On	24/11/2023 (DD/MM/YYYY)		
Name & capacity Patrick Vance, proxyhold	er	Signature S2255A/A39F46C	